| IMMUTEP LTD |
| Australien |
| Gesundheit |
| AU000000IMM6 / A2H81H |
| YP1B (Frankfurt) |
| FRA:YP1B, ETR:YP1B, YP1B:GR |
| - |
| https://www.immutep.com/ |
|
Immutep Limited is a late-stage biotechnology company specializing in the development of innovative immunotherapies for cancer and autoimmune diseases. Headquartered in Sydney, Australia, with operations spanning Europe and the United States, Immutep..
>Volltext.. |
| 40.54 Mio. EUR |
| -15.06 Mio. EUR |
| 2.36 Mio. EUR |
| -49.85 Mio. EUR |
| -48.51 Mio. EUR |
| -0.03 EUR |
| 0.7 Mio. EUR |
| 42.05 Mio. EUR |
| -35.93 Mio. EUR |
| 2.11 |
| - |
| -81.86% |
| - |
| - |
| - |
| - |
| IMMUTEP |
| 04.04.26 |
|
||||
|